Latest News

Tapinarof Cream Under FDA Review for Atopic Dermatitis Indication


 

On February 14, Dermavant Sciences announced that the company had submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration for tapinarof cream, 1%, for treating atopic dermatitis (AD) in adults and children 2 years of age and older.

Tapinarof cream, 1%, is an aryl hydrocarbon receptor agonist marketed under the brand name VTAMA that was approved in 2022 for treating plaque psoriasis in adults.

According to a Dermavant press release, the sNDA is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials and interim results from the phase 3 ADORING 3 open-label, long-term extension 48-week trial. In ADORING 1 and ADORING 2, tapinarof cream demonstrated statistically significant improvements in the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) treatment success, defined as a vIGA-AD score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline; demonstrated treatment success over vehicle at week 8; and met all key secondary endpoints with statistical significance, according to the company.

The most common adverse reactions in patients treated with VTAMA cream include folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus.

Recommended Reading

Atopic dermatitis is associated with increased prevalence of inflammatory bowel disease
MDedge Dermatology
Men with atopic dermatitis more likely to have poorer cognitive function
MDedge Dermatology
Novel Clinic Resulted in ‘Impressive’ Outcomes for Patients With Moderate to Severe Eczema
MDedge Dermatology
A Look at the Evidence Linking Diet to Skin Conditions
MDedge Dermatology
Commentary: Drug Comparisons and Contact Allergy in AD, February 2024
MDedge Dermatology
Diffusely Scattered Macules Following Radiation Therapy
MDedge Dermatology
Impact of Ketogenic and Low-Glycemic Diets on Inflammatory Skin Conditions
MDedge Dermatology
Review Finds No Short-term MACE, VTE risk with JAK Inhibitors For Dermatoses
MDedge Dermatology
Survey: Dermatology Residents Shortchanged on Sensitive Skin Education
MDedge Dermatology
Dupilumab Improves AD Affecting the Hands, Feet
MDedge Dermatology